Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mdCD7-CAR-NK-92MI
- Development stage
- Preclinical
- Lead developer
- PersonGen BioTherapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
mdCD7-CAR-NK-92MI is a monoclonal, bivalent chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting the CD7 antigen. Developed for the treatment of T-cell acute lymphoblastic leukemia (T-ALL), it utilizes the NK-92MI cell line, which is an interleukin-2 (IL-2) independent derivative of the NK-92 cell line. The CAR construct features a bivalent CD7-specific nanobody (VHH6-VHH6) linked to CD28 and 4-1BB costimulatory domains and a CD3ζ signaling domain. By targeting CD7, which is highly expressed in T-ALL but absent on a subset of normal T cells, and using NK cells as effectors, this therapy aims to avoid the fratricide common in CD7-targeted CAR-T therapies while providing a potent, off-the-shelf cytotoxic response. The 'md' prefix indicates a monoclonal derivative of the bivalent (d) CD7-CAR construct.
- Other names
- monoclonal bivalent CD7-CAR-NK-92MIdCD7-CAR-NK-92MI monoclonal cellsdCD-7-CAR-NK-92MI monoclonal cellsdCD 7-CAR-NK-92MI monoclonal cells
02
Targets
CD7 (CD7 antigen)
Beyond the preview
Go deeper on mdCD7-CAR-NK-92MI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mdCD7-CAR-NK-92MI.